Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT05032560
Other study ID # ABX464-921
Secondary ID
Status Completed
Phase Phase 1
First received
Last updated
Start date September 27, 2021
Est. completion date February 18, 2022

Study information

Verified date January 2023
Source Abivax S.A.
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The study consists of Part A, a randomized double-blind, single-ascending-dose study, and Part B, a randomized, double-blind, semi-sequential, escalating multiple-dose study, in healthy Japanese volunteers.


Description:

Part A includes the following two dose regimen groups: - 25 mg dose regimen group: ABX464 25 mg or placebo - 50 mg dose regimen group: ABX464 50 mg or placebo In each dose regimen group, 12 subjects will be randomly assigned, according to a 3:1 ratio, to receive either ABX464 (9 subjects) or its matching placebo (3 subjects). Part B includes the following two dose regimen groups: - 25 mg dose regimen group: ABX464 25 mg or placebo for 28 days - 50 mg dose regimen group: ABX464 50 mg or placebo for 28 days In each dose regimen group, 12 subjects will be randomly assigned, according to a 3:1 ratio, to receive either ABX464 (9 subjects) or its matching placebo (3 subjects).


Recruitment information / eligibility

Status Completed
Enrollment 48
Est. completion date February 18, 2022
Est. primary completion date February 18, 2022
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Male
Age group 20 Years to 45 Years
Eligibility Inclusion Criteria: 1. Male Japanese volunteers. 2. 20 to 45 years old. 3. Considered by the Investigator, as healthy based on history, physical examination, and complete laboratory evaluation (laboratory parameters should be within normal ranges of the study center's laboratory or considered not clinically significant by the Investigator). 4. Vital signs (supine blood pressure, resting pulse rate, body temperature) should be within normal ranges and no deviation from standard 12-lead electrocardiogram (ECG) should be observed at screening. Body mass index (BMI) should be between 18 (inclusive) and 27 kg/m² (inclusive). 5. Non-smokers at enrolment. 6. Subjects must understand, sign and date the written voluntary Informed Consent Form at the visit prior to any protocol-specific procedures. 7. Able and willing to comply with study visits and procedures as per protocol. 8. Males receiving the study treatment and their partners must agree to use a highly effective contraceptive method during the study and for 6 months after the last dose of study drug. Highly effective methods of contraception include true abstinence, intrauterine device (IUD) or hormonal contraception aiming at inhibition of ovulation, intrauterine hormone releasing system, bilateral tubal ligation, and vasectomized partner. True abstinence is defined when this is in line with the preferred and usual lifestyle of the subject. In each case of delayed menstrual period (over 1 month between menstruations) in a female partner of a male subject, confirmation of absence of pregnancy of the partner is required. Male subjects must not be planning pregnancy, should use a condom and must not donate sperm during the study and for 6 months after the last dose of study drug. Exclusion Criteria: 1. Acute disease state (e.g., nausea, vomiting, diarrhea, or fever within a week) or chronic infectious disease (positive results for hepatitis B surface antigen [HBsAg], hepatitis C virus antibody, human immunodeficiency virus antigen/antibody, tuberculosis determined by QuantiFERON-TB Gold Plus test). Subjects who have positive hepatitis B core antibody [HBcAb] can be enrolled but must have an undetectable hepatitis B virus [HBV] viral load (HBV DNA test). 2. Positive results for SARS-CoV-2 antigen determined by polymerase chain reaction method. 3. History of recent grade 3 or 4 opportunistic infection or underlying conditions that may predispose them to grade 3 or grade 4 infection. 4. History of cardiovascular, pulmonary, gastrointestinal, hepatic, pancreatic, renal, metabolic, hematological, neurological, psychiatric, or systemic disease that could jeopardize the safety of the subject or the validity of the study results. 5. Illicit drug or alcohol abuse, or dependence within a year. 6. Blood donation within 3 months prior to screening. 7. Use of any investigational or non-registered product within 3 months or within 5 half-lives preceding baseline, whichever is longer. 8. Use of any immunosuppressive drugs (except topical steroids) within 3 months prior to first dose. 9. Any history of hypersensitivity to drugs. 10. Any condition, which in the opinion of the Investigator, could compromise the subject's safety or adherence to the study protocol

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
ABX464
Drug: ABX464 ABX464 is a new anti-inflammatory drug
Placebo
Drug: Matching Placebo placebo matching with ABX464

Locations

Country Name City State
Japan Medical Corporation Heishinkai OPHAC Hospital Osaka-shi Osaka

Sponsors (1)

Lead Sponsor Collaborator
Abivax S.A.

Country where clinical trial is conducted

Japan, 

Outcome

Type Measure Description Time frame Safety issue
Primary Incidence of adverse events (AEs) and SAEs number of incidences of all adverse events (AEs) (causally related and non-related) and SAEs, will be described further categorized by severity 6 weeks
Primary incidence of treatment-emergent serious adverse events number of incidences of treatment-emergent serious adverse events will be described 6 weeks
Primary incidence of treatment-emergent adverse events of special interest (AESIs). number of incidences of treatment-emergent adverse events of special interest (AESIs) will be described. 6 weeks
Primary incidence of clinically significant laboratory abnormalities number of incidences of clinically significant laboratory abnormalities will be described 6 weeks
Secondary Maximum Plasma Concentration [Cmax] Cmax of ABX464 will be derived from the plasma concentrations 42 days
Secondary Area under the plasma concentration versus time curve (AUC) AUC of ABX464 will be derived from the plasma concentrations 42 days
Secondary Time to reach the maximum plasma concentration (tmax) Tmax of ABX464 will be derived from the plasma concentrations 42 days
Secondary miR124 level concentration of miR124 expression will be measured in blood 42 days
See also
  Status Clinical Trial Phase
Completed NCT05001152 - Taste Assessment of Ozanimod Phase 1
Completed NCT05029518 - 3-Way Crossover Study to Compare the PK (Pharmokinetics) and to Evaluate the Effect of Food on the Bioavailability Phase 1
Completed NCT04493255 - A Study to Determine the Metabolism and Elimination of [14C]E7090 in Healthy Male Participants Phase 1
Completed NCT03457649 - IV Dose Study to Assess the Safety, Tolerability, PK, PD and Immunogenicity of ARGX-113 in Healthy Volunteers Phase 1
Completed NCT00995891 - Collection of Blood, Bone Marrow, and Buccal Mucosa Samples From Healthy Volunteers for Center for Human Immunology, Autoimmunity, and Inflammatory Diseases (CHI) Laboratory Research Studies
Completed NCT05043766 - Evaluation of Oral PF614 Relative to OxyContin Phase 1
Completed NCT05050318 - Annual Study for Collection of Serum Samples in Children and Older Adults Receiving the 2021-2022 Formulations of Fluzone Quadrivalent Vaccine and Fluzone High-Dose Quadrivalent Vaccine, Respectively Phase 4
Completed NCT04466748 - A Multiple Ascending Dose Pharmacology Study of Anaprazole in Healthy Chinese Subjects Phase 1
Completed NCT00746733 - Vyvanse and Adderall XR Given Alone and in Combination With Prilosec OTC Phase 1
Recruiting NCT05929651 - Study of Immunogenicity and Safety of MenQuadfi® as a Booster Vaccine in Toddlers 12 to 23 Months, Regardless of the Quadrivalent Meningococcal Conjugate Vaccine Used for Priming in Infancy Phase 4
Completed NCT05954039 - Evaluation of the Efficacy of a Dietary Supplement on Hair Loss and Hair Aspect N/A
Completed NCT05045716 - A Study of Subcutaneous Lecanemab in Healthy Participants Phase 1
Active, not recruiting NCT02747927 - Efficacy, Safety and Immunogenicity of Takeda's Tetravalent Dengue Vaccine (TDV) in Healthy Children Phase 3
Completed NCT05533801 - A Study to Demonstrate the Bioequivalence of Lecanemab Supplied in Vials and a Single-Use Auto-Injector (AI) in Healthy Participants Phase 1
Not yet recruiting NCT03931369 - Adaptation of Thirst to a Single Administration of Tolvaptan (TOLVATHIRST) Phase 2
Completed NCT03279146 - A Single Dose Study Evaluating PK of TXL Oral Formulations in Healthy Subjects Phase 1
Completed NCT06027437 - A Study to Assess the Relative Biological Availability and the Effect of Food on the Drug Levels of Danicamtiv in Healthy Adult Participants Phase 1
Recruiting NCT05619874 - Effects of Two Virtual HIFCT Programs in Adults With Abdominal Obesity N/A
Completed NCT05553418 - Investigational On-body Injector Clinical Study N/A
Completed NCT04092712 - Study Evaluating Pharmacokinetics and Mass Balance of [14C]-CTP-543 in Healthy Adult Male Volunteers Phase 1